(LNTH) Lantheus Holdings - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 6.399m USD | Total Return: 31.5% in 12m
Avg Turnover: 102M
EPS Trend: -15.2%
Qual. Beats: 2
Rev. Trend: 88.3%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Supp Ema20, Rs Leader, Idiosyncratic Leader, Tailwind, Pullback 52w, Garp
Lantheus Holdings, Inc. (LNTH) is a Massachusetts-based healthcare company specializing in the development and commercialization of diagnostic and therapeutic radiopharmaceuticals. Its portfolio includes PYLARIFY for prostate cancer imaging and DEFINITY, a leading ultrasound enhancing agent for echocardiography. The company operates within the specialized radiopharmaceutical sector, which requires high-barrier infrastructure for the production and distribution of isotopes with short half-lives.
The company’s pipeline focuses on precision medicine, integrating artificial intelligence software like aPROMISE and PYLARIFY AI to quantify disease burden. Lantheus utilizes a business model centered on strategic collaborations with major industry players such as GE Healthcare and Regeneron to expand its market reach and R&D capabilities. To better understand these market dynamics, you can review additional data on ValueRay. The firm is currently advancing several late-stage therapies targeting neuroendocrine tumors and Alzheimer’s disease.
- PYLARIFY market share expansion drives oncology segment revenue growth
- CMS reimbursement policy changes impact radiopharmaceutical product margins
- Pipeline transition toward radiopharmaceutical therapies diversifies long-term earnings
- Strategic partnerships with GE Healthcare and Regeneron expand global distribution
- DEFINITY demand stability supports consistent cash flow for R&D investment
| Net Income: 279.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -7.06 > 1.0 |
| NWC/Revenue: 39.40% < 20% (prev 76.51%; Δ -37.12% < -1%) |
| CFO/TA 0.17 > 3% & CFO 407.7m > Net Income 279.0m |
| Net Debt (127.2m) to EBITDA (369.2m): 0.34 < 3 |
| Current Ratio: 2.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.8m) vs 12m ago -7.96% < -2% |
| Gross Margin: 60.48% > 18% (prev 0.64%; Δ 5.98k% > 0.5%) |
| Asset Turnover: 70.25% > 50% (prev 74.77%; Δ -4.52% > 0%) |
| Interest Coverage Ratio: 14.64 > 6 (EBITDA TTM 369.2m / Interest Expense TTM 19.8m) |
| A: 0.26 (Total Current Assets 942.3m - Total Current Liabilities 333.2m) / Total Assets 2.35b |
| B: 0.34 (Retained Earnings 797.9m / Total Assets 2.35b) |
| C: 0.13 (EBIT TTM 290.1m / Avg Total Assets 2.20b) |
| D: 0.70 (Book Value of Equity 796.8m / Total Liabilities 1.13b) |
| Altman-Z'' = 4.43 = AA |
| DSRI: 1.01 (Receivables 355.7m/348.7m, Revenue 1.55b/1.54b) |
| GMI: 1.06 (GM 60.48% / 64.04%) |
| AQI: 2.42 (AQ_t 0.53 / AQ_t-1 0.22) |
| SGI: 1.01 (Revenue 1.55b / 1.54b) |
| TATA: -0.05 (NI 279.0m - CFO 407.7m) / TA 2.35b) |
| Beneish M = -2.17 (Cap -4..+1) = BB |
As of May 30, 2026, the stock is trading at USD 99.30 with a total of 1,109,697 shares traded.
Over the past week, the price has changed by +5.11%,
over one month by +22.34%,
over three months by +32.56% and
over the past year by +31.49%.
Lantheus Holdings has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy LNTH.
- StrongBuy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 104.1 | 4.8% |
P/E Trailing = 23.512
P/E Forward = 18.1818
P/S = 4.1383
P/B = 5.5375
P/EG = 0.61
Revenue TTM = 1.55b USD
EBIT TTM = 290.1m USD
EBITDA TTM = 369.2m USD
Long Term Debt = 569.6m USD (from longTermDebt, last quarter)
Short Term Debt = 803k USD (from shortTermDebt, last quarter)
Debt = 625.8m USD (corrected: LT Debt 569.6m + ST Debt 803k) + Leases 55.3m
Net Debt = 127.2m USD (calculated: Debt 625.8m - CCE 498.6m)
Enterprise Value = 6.53b USD (6.40b + Debt 625.8m - CCE 498.6m)
Interest Coverage Ratio = 14.64 (Ebit TTM 290.1m / Interest Expense TTM 19.8m)
EV/FCF = 17.56x (Enterprise Value 6.53b / FCF TTM 371.7m)
FCF Yield = 5.70% (FCF TTM 371.7m / Enterprise Value 6.53b)
FCF Margin = 24.04% (FCF TTM 371.7m / Revenue TTM 1.55b)
Net Margin = 18.05% (Net Income TTM 279.0m / Revenue TTM 1.55b)
Gross Margin = 60.48% ((Revenue TTM 1.55b - Cost of Revenue TTM 611.0m) / Revenue TTM)
Gross Margin QoQ = 61.20% (prev 59.21%)
Tobins Q-Ratio = 2.78 (Enterprise Value 6.53b / Total Assets 2.35b)
Interest Expense / Debt = 3.17% (Interest Expense 19.8m / Debt 625.8m)
Taxrate = 24.29% (38.0m / 156.4m)
NOPAT = 219.6m (EBIT 290.1m * (1 - 24.29%))
Current Ratio = 2.83 (Total Current Assets 942.3m / Total Current Liabilities 333.2m)
Debt / Equity = 0.52 (Debt 625.8m / totalStockholderEquity, last quarter 1.21b)
Debt / EBITDA = 0.34 (Net Debt 127.2m / EBITDA 369.2m)
Debt / FCF = 0.34 (Net Debt 127.2m / FCF TTM 371.7m)
Total Stockholder Equity = 1.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.68% (Net Income 279.0m / Total Assets 2.35b)
RoE = 24.33% (Net Income TTM 279.0m / Total Stockholder Equity 1.15b)
RoCE = 16.90% (EBIT 290.1m / Capital Employed (Equity 1.15b + L.T.Debt 569.6m))
RoIC = 12.25% (NOPAT 219.6m / Invested Capital 1.79b)
WACC = 6.47% (E(6.40b)/V(7.02b) * Re(6.87%) + D(625.8m)/V(7.02b) * Rd(3.17%) * (1-Tc(0.24)))
Discount Rate = 6.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -2.79%
[DCF] Terminal Value 73.10% ; FCFF base≈411.3m ; Y1≈360.7m ; Y5≈291.4m
[DCF] Fair Price = 69.89 (EV 4.68b - Net Debt 127.2m = Equity 4.55b / Shares 65.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -15.20 | EPS CAGR: -1.45% | SUE: 1.06 | # QB: 2
Revenue Correlation: 88.34 | Revenue CAGR: 11.24% | SUE: 1.44 | # QB: 3
EPS current Quarter (2026-06-30): EPS=1.29 | Chg30d=+2.17% | Revisions=+8% | Analysts=12
EPS next Quarter (2026-09-30): EPS=1.29 | Chg30d=-1.91% | Revisions=-47% | Analysts=12
EPS current Year (2026-12-31): EPS=5.32 | Chg30d=+2.45% | Revisions=+73% | GrowthEPS=-12.5% | GrowthRev=-5.0%
EPS next Year (2027-12-31): EPS=6.37 | Chg30d=+1.31% | Revisions=+50% | GrowthEPS=+19.9% | GrowthRev=+13.1%
[Analyst] Revisions Ratio: +73%